In the News

Dr. Todd Levine Interviewed on Arizona ABC15 About New Alzheimer’s Treatment

Dr. Todd Levine Interviewed on Arizona ABC15 About New Alzheimer’s Treatment

Aducanumab, the first treatment for Alzheimer’s disease to be approved in nearly two decades, has generated a fair share of interest—and controversy—since it was given approval by the FDA on June 7. Patients with Alzheimer’s and their families are eager to find out if the drug could help them or a loved one, while clinicians try to understand the data behind the drug and the context for its appropriate use.

CND Life Sciences’ co-founder, Dr. Todd Levine, who also serves as Medical Director of Neurology at HonorHealth, appeared on Arizona’s ABC15 to give his perspective on the new treatment.

WATCH THE INTERVIEW
CND Life Sciences

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.